• Disclosure
  • Privacy Policy
  • DMCA Policy
  • CCPA
  • Medical Disclaimer
Monday, January 30, 2023
Massachusetts Digital News
  • Home
  • US
  • Business
  • World
  • Boston
  • Worcester
  • Springfield
  • Cambridge
  • Lowell
  • Brockton
  • Press Releases
  • Videos
No Result
View All Result
  • Home
  • US
  • Business
  • World
  • Boston
  • Worcester
  • Springfield
  • Cambridge
  • Lowell
  • Brockton
  • Press Releases
  • Videos
No Result
View All Result
No Result
View All Result
Home Springfield

Sulthiame Found Safe And Tolerable For Obstructive Sleep… : Neurology Today

by Duong
April 7, 2022
in Springfield
sulthiame-found-safe-and-tolerable-for-obstructive-sleep…-:-neurology-today
Share on FacebookShare on Twitter
Video.00132985 202204070 00005.feature

By Susan Kreimer

April 7, 2022

Article In Brief

In a four-week clinical trial, those taking sulthiame experienced an apnea hypopnea index reduction equal to or greater than 50 percent. In addition, 40 percent of the patients on the drug had improved nocturnal oxygenation and sleep quality. Experts say that while some patients will benefit from the drug, they don’t believe that it will replace the current standard of care—CPAP.

Sulthiame had an acceptable safety and tolerability profile in patients with moderate-to-severe obstructive sleep apnea (OSA), according to a study published online on February 24 in the American Journal of Respiratory & Critical Care Medicine.

Sulthiame is a carbonic anhydrase inhibitor, which mitigates the ventilatory instability that appears to be an underlying mechanism in OSA. Initial randomized controlled studies on carbonic anhydrase inhibitors have yielded inconclusive results, however.

In the current four-week, randomized, placebo-controlled, double-blind trial, the investigators observed that those taking sulthiame experienced a clinically relevant OSA improvement—an apnea hypopnea index reduction equal to or greater than 50 percent. In addition, 40 percent of the patients on the drug had improved nocturnal oxygenation and sleep quality.

The trial demonstrates that “sleep apnea may be treated pharmacologically, and sulthiame provides a strategy to be further evaluated for this indication,” the study’s lead author, Jan Hedner MD, PhD, a professor of respiratory medicine at Sahlgrenska University Hospital, a part of the University of Gothenburg in Sweden, told Neurology Today.

Patients with OSA suffer from repetitive episodes of airway collapse, deranged blood gases, autonomic activation, and sleep fragmentation. Based on current diagnostic criteria, 425 million middle-aged people worldwide are estimated to have moderate-to-severe OSA.

The condition is linked to cardiometabolic diseases such as hypertension, in particular therapy-resistant hypertension, arrhythmia, stroke, myocardial infarction, dyslipidemia, and diabetes. OSA also can induce excessive sleepiness, heighten the risk of accidents, and decrease quality of life.

“Hence, the burden of illness and the health economic consequences of OSA are considerable,” the authors noted. “The mainstay therapy in OSA, continuous positive airway pressure (CPAP), is highly effective but limited by incomplete long-term compliance. Other therapies such as upper airway surgery, intraoral devices, position trainers, and implantable nerve/muscle stimulation systems have a less predictable efficacy. There is an unmet medical need for an effective drug therapy in OSA.”

Dr. Hedner told Neurology Today that the new study has multiple strengths. In addition to being a randomized controlled trial, its advantages included stringent evaluation using state-of-the-art analysis equipment, a dose-finding design, and therapeutic drug monitoring.

When asked about any concerns in prescribing this agent, Dr. Hedner acknowledged the potential for dose-dependent side effects but pointed out that the study adequately addressed safety.

The current study also did not document the positive outcomes on subjective daytime markers, most likely due to the poor sensitivity of questionnaires or the trial’s short duration. In this context, the markers refer to detectable daytime symptoms related to the disorder such as sleepiness, cognitive dysfunction, and reaction time, Dr. Hedner said.

The lack of a significant daytime effect possibly might be explained by side effects in the highest 400 mg group, Dr. Hedner said, confounded by the patient reports that masked potential changes. Alternatively, the questionnaires used were too insensitive and did not detect potential changes. It is also possible that duration of treatment in the study was too short to detect a change.

“A change in one or several of these means that the patient may trace a positive effect of intervention beyond the supposed immediate effect on health,” he said.

The study’s authors concluded that large-scale clinical studies of sulthiame in OSA are warranted. Dr. Hedner noted that the study’s positive findings have led to a continued multicentric larger scale efficacy trial, which was launched in December 2021.

Study Details

For the study, investigators recruited male and female patients with OSA who had previously terminated CPAP therapy due to non-acceptance or lack of tolerability. To be eligible, participants had to be between 18 to 75 years old, have a body mass index of greater than or equal to 20 kg/m2 and less than or equal to 35 kg/m2, an apnea hypopnea index (AHI) of greater than or equal to 15, and an Epworth Sleepiness Scale score of greater than or equal to six.

The researchers excluded patients who had undergone OSA treatment within four weeks of the baseline visit as well as those with a central sleep apnea syndrome, dominant Cheyne-Stokes respiration, or a significant sleep disorder including periodic limb movements or parasomnia.

The investigators did report adverse events in the patients randomized to sulthiame. Seventy-nine percent of those assigned to the highest dose, 400 mg of sulthiame experienced intermittent paresthesia as did 67 percent of those taking the 200 mg dose—this compared with 18 percent of patients randomly assigned to placebo. Eighteen percent of patients receiving the 400 mg dose reported dyspnea. And six people in the higher-dose group withdrew from the trial due to adverse events. However, no serious adverse events occurred.

Sulthiame decreased the apnea-hypopnea index (AHI) from 55.3 to 33.1 events per hour (-41.0 percent) in the 400 mg group and from 61.2 to 40.7 events per hour (-32.1 percent) after 200 mg (p<0.001, respectively). Corresponding placebo values were 53.9 and 50.9 events per hour (-5.4 percent). The AHI reduction threshold of greater than or equal to 50 percent was reached in 40 percent of those taking 400 mg, 25 percent on 200 mg, and 5 percent, following placebo. Mean overnight oxygen saturation improved by 1.1 percent after 400 mg and 200 mg (p<0.001 and p=0.034, respectively).

On average, sulthiame lowered OSA by more than 20 events per hour, one of the most notable declines observed in a drug trial for OSA. As a result, larger scale clinical studies of this pharmacological agent are justified, the authors wrote.

Expert Commentary

Considering that some patients are reluctant or find it difficult to use CPAP for OSA, additional pharmacological options would be an important development, said Karin Johnson, MD, FAAN, FAASM, associate professor at UMass Chan School of Medicine-Baystate and medical director of the Baystate Health regional sleep medicine program in Springfield, MA.

“Ventilatory instability is seen quite commonly in patients with OSA and tends to lead to a higher number of events and more difficulty treating some patients with CPAP therapy who develop treatment-emergent central sleep apnea,” she said.

Dr. Johnson added that it’s worthwhile to consider referring these patients to a sleep specialist, who can discuss other treatment options including medications. However, she advised that clinicians caution patients about the likelihood that a medication alone may not work as well as PAP therapy or other treatment options that also address anatomical obstruction.

The study’s results are not surprising, she said. The reduction in AHI with sulthiame mirrors the outcomes with another carbonic anhydrase inhibitor, acetazolamide, which she has used successfully in some patients who have high loop-gain and a tendency toward a periodic breathing pattern.

Nonetheless, as this trial suggests, the reduction in AHI does not always correlate well with clinical outcomes such as reduction in sleepiness or improved sleep quality, Dr. Johnson pointed out. Sleepiness and quality-of-life scales did not improve in this study, probably due to the fact that OSA stems from a combination of both structural and ventilatory instability causes, she said. Sulthiame targets the instability component alone and does not improve breathing adequately enough to make a clinically significant difference in most patients, Dr. Johnson explained.

In many patients in this study, the residual AHI ranged between 20 and 60 events per hour on treatment, which still represents a high degree of residual obstruction.

“There are likely to be some patients who will benefit from sulthiame alone if other treatments are not a possibility,” she said. “Most likely, it will be best to use in combination with CPAP therapy or with other alternative treatments that help the obstructive component, such as lateral sleeping, nasal congestion treatments, mandibular advancement devices, or newer treatments like nasal expiratory positive airway pressure, oral negative pressure, or daytime tongue stimulation.”

Logan Schneider, MD, a consultant neurologist at the Stanford/VA Alzheimer’s Center in Palo Alto, CA, echoed similar sentiments, welcoming a pharmacological agent to the arsenal of treatments for OSA.

“At first blush, from a general perspective, obviously this is what everybody wants for sleep apnea—a pill to treat it instead of the standard CPAP devices,” said Dr. Schneider, who is also a clinical assistant professor affiliated with the Stanford Sleep Center at the Stanford University School of Medicine.

figure1

“While this is a good treatment, particularly for people who cant tolerate the standard-of-care therapy, which is the CPAP device, its certainly not a replacement for it in the average person.”—DR. LOGAN SCHNEIDER

However, most people in the study—even those receiving the highest dose of the medication—still experienced severe OSA. “While this is a good treatment, particularly for people who can’t tolerate the standard-of-care therapy, which is the CPAP device, it’s certainly not a replacement for it in the average person,” he said.

Neurologists acknowledge that OSA is more complicated than they initially thought, with multiple contributing factors, Dr. Schneider said, adding that “each person is a mix of what you call underlying pathophysiology—causes for a disease state.”

The researchers randomly selected patients, without any particular inclusion criteria pertaining to OSA endotypes such as loop-gain—the way that the body manages carbon dioxide and oxygen in the blood through communication between the lungs and brainstem. The other endotypes believed to contribute to OSA are Pcrit, arousal threshold, and muscle tone in the tongue. However, the study didn’t distinguish between the factors specifically at play in relation to therapeutic response, so that should be investigated in future trials to determine the appropriate patient population for this medication, Dr. Schneider noted.

“Sulthiame is not a silver bullet,” he said. “You don’t use it indiscriminately in all sleep apnea patients.” Instead, he described it as “possibly another option, which obviously needs to go through more rigorous validation.”

He added that this small study “highlights that some patients might benefit from this therapy if they can’t tolerate the primary gold standard therapy, or if we find better ways to categorize obstructive sleep apnea based on what causes it.”

Link Up for More Information

• Hedner J, Stemlof K, Zou D, et al. A randomized controlled trial exploring safety and tolerability of sulthiame in sleep apnea https://www.atsjournals.org/doi/10.1164/rccm.202109-2043OC. Am J Respir Crit Care Med 2022: Epub 2022 Feb 24.

Read More Here

Related Posts

obituaries-in-dover,-nh-|-foster's-daily-democrat

Obituaries In Dover, NH | Foster's Daily Democrat

by Duong
April 14, 2022
0

Helen E (Michalak) Simpson, 97, of Portsmouth, NH passed away peacefully in her sleep April 09, 2022 at the Pines Assisted Living Facility in Newmarket, NH. Born February 24, 1925 in Springfield MA, she was the daughter of Josephine and Peter Michalak. She graduated from Technical High School in 1943...

garden-notes:-april-13,-2022

Garden Notes: April 13, 2022

by NewsReporter
April 13, 2022
0

Berkshire Botanical Garden ornamental vegetable garden.Upcoming programs at Berkshire Botanical GardenSTOCKBRIDGE - Berkshire Botanical Garden presents the following upcoming programs. Wednesday, April 20, and April 27, 4 p.m. 5:30 p.m., “New England Spring Wildflower Primer,” takes place online. This 2-part series on wildflowers will present an overview of the native...

pedestrian-fatally-struck-on-interstate-291-in-springfield

Pedestrian Fatally Struck On Interstate 291 In Springfield

by Duong
April 12, 2022
0

A pedestrian died Monday night after being hit by a vehicle on Interstate 291 in Springfield, Massachusetts, state police said. Massachusetts State Police were at the scene of the crash on I-291 eastbound, near Exit 3, just before 9 p.m. No other injuries were reported, state police said. Only one...

springfield-families-celebrate-the-season-at-bunny-hop-spring-party

Springfield Families Celebrate The Season At Bunny Hop Spring Party

by NewsReporter
April 11, 2022
0

Springfield families celebrate the season at Bunny Hop Spring PartyPublished: Apr. 10, 2022 at 8:36 PM EDT|Updated: 7 hours agoSPRINGFIELD, Mass. (WGGB/WSHM) -Springfield Mayor Domenic Sarno, Springfield Together, Inc., Strong Young Minds, and iHeartRadio all came together Sunday to host the Bunny Hop Spring Party at Riverfront Park. The community...

Massachusetts Digital News

© 2021 Massachusetts Digital News

Navigate Site

  • Disclosure
  • Privacy Policy
  • DMCA Policy
  • CCPA
  • Medical Disclaimer

Follow Us

No Result
View All Result
  • Home
  • DMCA Policy
  • Medical Disclaimer
  • Privacy Policy
  • Disclosure
  • CCPA
  • Terms of Use

© 2021 Massachusetts Digital News

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT